---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-093921"
form_type: "8-K"
ticker: "SGMT"
cik: "0001400118"
company_name: "Sagimet Biosciences Inc."
filed_at: "2023-08-21T23:59:59+00:00"
generated_at: "2026-06-11T06:04:32.263543+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Sagimet Q2 net loss $6.8M; IPO raised $86.2M net; denifanstat 67% fat reduction

## Summary
- IPO closed July 18: 6,026,772 shares at $16; gross proceeds $96.4M, net $86.2M.
- Cash $18.5M at June 30; combined with IPO proceeds extends runway into Q1 2025.
- Phase 2b FASCINATE-2 interim: 67% denifanstat achieved ≥30% liver fat reduction vs 18% placebo (p<0.001).
- Tony Rimac appointed CFO (previously COO) after Dennis Hom departure; Liz Rozek as General Counsel & CCO.
- Net loss $13.4M for H1 2023; R&D $9.2M, G&A $4.7M; no FY2023 guidance provided.

## SEC filing metadata
- accession: 0001104659-23-093921
- form_type: 8-K
- ticker: SGMT
- cik: 0001400118
- company_name: Sagimet Biosciences Inc.
- filed_at: 2023-08-21T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1400118/000110465923093921/0001104659-23-093921-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1400118/000110465923093921/tm2323988d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-093921
- JSON: https://secwatch.observer/filing/0001104659-23-093921.json
- Plain text: https://secwatch.observer/filing/0001104659-23-093921.txt

## Key facts
- Earnings Releases
  Sagimet Biosciences Inc. reported the second quarter ended June 30, 2023 results: net income Net loss for the second quarter ended June 30, 2023 was $6.8 million.
  - Period: the second quarter ended June 30, 2023
  - Net income: Net loss for the second quarter ended June 30, 2023 was $6.8 million
  - Result: reported results
  source text: Net loss for the second quarter ended June 30, 2023 was $6.8 million compared to a net loss of $7.1 million for the second quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1400118/000110465923093921/0001104659-23-093921-index.htm
- Earnings Releases
  Sagimet Biosciences Inc. reported the six months ended June 30, 2023 results: net income The net loss for the six months ended June 30, 2023 totaled $13.4 million.
  - Period: the six months ended June 30, 2023
  - Net income: The net loss for the six months ended June 30, 2023 totaled $13.4 million
  - Result: reported results
  source text: The net loss for the six months ended June 30, 2023 totaled $13.4 million compared to $15.8 million for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1400118/000110465923093921/0001104659-23-093921-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.